This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Go, R. S. Articles by Adjei, A. A. Search for Related Content PubMed PubMed Citation Articles by Go, R. S. Articles by Adjei, A. A. Social Bookmarking                            What's this?

Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin

From the Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN.

Address reprint requests to Alex A. Adjei, MD, PhD, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; Email adjei.alex{at}mayo.edu

ABSTRACT

PURPOSE: To review the pharmacodynamics, pharmacokinetics, toxicities, and relative clinical activities of cisplatin and carboplatin. Through a search of the MEDLINE database, we identified phase III clinical trials and pharmacologic studies comparing cisplatin and carboplatin published in the English language medical literature from January 1966 to December 1997.

RESULTS: Prospective randomized trials comparing cisplatin to carboplatin were identified for ovarian (n = 12), germ cell (n = 4), non–small-cell lung (n = 1), small-cell lung (n = 3), and head and neck (n = 4) cancers. Carboplatin and cisplatin were equally effective in suboptimally debulked ovarian cancer and extensive-stage small-cell lung cancer. One study each showed a trend toward better survival in favor of cisplatin for patients with optimally debulked ovarian and limited-stage small-cell lung cancers. These results were, however, based on subset analyses. In germ cell tumors, carboplatin was inferior because of lower relapse-free survival rates. Cisplatin produced superior response rates and survival in head and neck cancers. There are no published randomized phase III studies of bladder, cervical, endometrial, and esophageal cancers.

CONCLUSION: Carboplatin does not possess equivalent activity to cisplatin in all platinum-sensitive tumors. Carboplatin can replace cisplatin in chemotherapy regimens for suboptimally debulked ovarian cancer. Two ongoing studies will address the same question in optimally debulked disease. Carboplatin can also be substituted for cisplatin in the treatment of non–small-cell and extensive-stage small-cell lung cancers. Its role in limited-stage small-cell lung cancer needs to be investigated further. Carboplatin is inferior to cisplatin in germ cell, head and neck, and esophageal cancers. Randomized studies are needed to determine whether carboplatin has equivalent efficacy to cisplatin in bladder, cervical, and endometrial cancers.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. S. Boss, W. S. Siegel-Lakhai, N. E. van Egmond-Schoemaker, D. Pluim, H. Rosing, W. W. ten Bokkel Huinink, J. H. Beijnen, and J. H.M. Schellens Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors Clin. Cancer Res., July 1, 2009; 15(13): 4475 - 4483. [Abstract] [Full Text] [PDF]

				Y. Sawamura, Y. Kamoshima, T. Kato, T. Tajima, and J. Tsubaki Chemotherapy with Cisplatin and Vincristine for Optic Pathway/Hypothalamic Astrocytoma in Young Children Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 277 - 283. [Abstract] [Full Text] [PDF]

				K. K. Ang Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes Oncologist, August 1, 2008; 13(8): 899 - 910. [Abstract] [Full Text] [PDF]

				K. K. Filipski, W. J. Loos, J. Verweij, and A. Sparreboom Interaction of Cisplatin with the Human Organic Cation Transporter 2 Clin. Cancer Res., June 15, 2008; 14(12): 3875 - 3880. [Abstract] [Full Text] [PDF]

				A. A. Chiappori, E. Haura, F. A. Rodriguez, D. Boulware, R. Kapoor, A. M. Neuger, R. Lush, B. Padilla, M. Burton, C. Williams, et al. Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1464 - 1469. [Abstract] [Full Text] [PDF]

				T. Sher, G. K. Dy, and A. A. Adjei Small Cell Lung Cancer Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367. [Abstract] [Full Text] [PDF]

				J. Rousseau, C. Boudou, R. F. Barth, J. Balosso, F. Esteve, and H. Elleaume Enhanced Survival and Cure of F98 Glioma Bearing Rats following Intracerebral Delivery of Carboplatin in Combination with Photon Irradiation Clin. Cancer Res., September 1, 2007; 13(17): 5195 - 5201. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, et al. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis J Natl Cancer Inst, June 6, 2007; 99(11): 847 - 857. [Abstract] [Full Text] [PDF]

				M. Tiseo, L. Boni, and A. Ardizzoni Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference? J. Clin. Oncol., September 1, 2005; 23(25): 6276 - 6277. [Full Text] [PDF]

				J. R. Goffin, I. C. Anderson, J. G. Supko, J. P. Eder Jr., G. I. Shapiro, T. J. Lynch, M. Shipp, B. E. Johnson, and A. T. Skarin Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3417 - 3424. [Abstract] [Full Text] [PDF]

				K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., October 1, 2004; 22(19): 3852 - 3859. [Abstract] [Full Text] [PDF]

				G.-C. Huang, S.-Y. Liu, M.-H. Lin, Y.-Y. Kuo, and Y.-C. Liu The Synergistic Cytotoxicity of Cisplatin and Taxol in Killing Oral Squamous Cell Carcinoma Jpn. J. Clin. Oncol., September 1, 2004; 34(9): 499 - 504. [Abstract] [Full Text] [PDF]

				E. A. Perez Carboplatin in Combination Therapy for Metastatic Breast Cancer Oncologist, September 1, 2004; 9(5): 518 - 527. [Abstract] [Full Text] [PDF]

				K. A. Gelmon, D. Stewart, K. N. Chi, S. Chia, C. Cripps, S. Huan, S. Janke, D. Ayers, D. Fry, J. A. Shabbits, et al. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131 Ann. Onc., July 1, 2004; 15(7): 1115 - 1122. [Abstract] [Full Text] [PDF]

				D. Fortin, J. A. Salame, A. Desjardins, and A. Benko Technical Modification in the Intracarotid Chemotherapy and Osmotic Blood-Brain Barrier Disruption Procedure to Prevent the Relapse of Carboplatin-Induced Orbital Pseudotumor AJNR Am. J. Neuroradiol., May 1, 2004; 25(5): 830 - 834. [Abstract] [Full Text] [PDF]

				D. Hagrman, J. Goodisman, and A.-K. Souid Kinetic Study on the Reactions of Platinum Drugs with Glutathione J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 658 - 666. [Abstract] [Full Text] [PDF]

				A. Inoue, Y. Saijo, T. Kikuchi, K. Gomi, T. Suzuki, M. Maemondo, M. Miki, T. Sato, and T. Nukiwa Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis Ann. Onc., January 1, 2004; 15(1): 51 - 54. [Abstract] [Full Text] [PDF]

				R. F. Ozols, B. N. Bundy, B. E. Greer, J. M. Fowler, D. Clarke-Pearson, R. A. Burger, R. S. Mannel, K. DeGeest, E. M. Hartenbach, and R. Baergen Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., September 1, 2003; 21(17): 3194 - 3200. [Abstract] [Full Text] [PDF]

				M. Massimino, F. Spreafico, G. Cefalo, R. Riccardi, J. D. Tesoro-Tess, L. Gandola, D. Riva, A. Ruggiero, L. Valentini, E. Mazza, et al. High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma J. Clin. Oncol., October 15, 2002; 20(20): 4209 - 4216. [Abstract] [Full Text] [PDF]

				J.-C. Soria and T. Le Chevalier Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann. Onc., October 1, 2002; 13(10): 1515 - 1517. [Full Text] [PDF]

				K. Zhang, M. Chew, E. B. Yang, K. P. Wong, and P. Mack Modulation of Cisplatin Cytotoxicity and Cisplatin-Induced DNA Cross-Links in HepG2 Cells by Regulation of Glutathione-Related Mechanisms Mol. Pharmacol., April 1, 2001; 59(4): 837 - 843. [Abstract] [Full Text]

				N. D. Doolittle, L. L. Muldoon, R. E. Brummett, R. M. Tyson, C. Lacy, J. S. Bubalo, D. F. Kraemer, M. C. Heinrich, J. A. Henry, and E. A. Neuwelt Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors Clin. Cancer Res., March 1, 2001; 7(3): 493 - 500. [Abstract] [Full Text]

				E. Pertusini, J. Ratajczak, M. Majka, D. Vaughn, M. Z. Ratajczak, and A. M. Gewirtz Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy Blood, February 1, 2001; 97(3): 638 - 644. [Abstract] [Full Text] [PDF]

				W.-C. Su, S.-L. Chang, T.-Y. Chen, J.-S. Chen, and C.-J. Tsao Comparison of In Vitro Growth-inhibitory Activity of Carboplatin and Cisplatin on Leukemic Cells and Hematopoietic Progenitors: the Myelosuppressive Activity of Carboplatin May Be Greater Than Its Antileukemic Effect Jpn. J. Clin. Oncol., December 1, 2000; 30(12): 562 - 567. [Abstract] [Full Text] [PDF]

				M. Ando, H. Minami, Y. Ando, H. Saka, S. Sakai, M. Yamamoto, Y. Sasaki, K. Shimokata, and Y. Hasegawa Multi-Institutional Validation Study of Carboplatin Dosing Formula Using Adjusted Serum Creatinine Level Clin. Cancer Res., December 1, 2000; 6(12): 4733 - 4738. [Abstract] [Full Text]

				H. Thomas, A. V. Boddy, M. W. English, R. Hobson, J. Imeson, I. Lewis, B. Morland, A. D. J. Pearson, R. Pinkerton, L. Price, et al. Prospective Validation of Renal Function-Based Carboplatin Dosing in Children With Cancer: A United Kingdom Children's Cancer Study Group Trial J. Clin. Oncol., November 1, 2000; 18(21): 3614 - 3621. [Abstract] [Full Text] [PDF]